Telemedicine Adoption and Low-Value Care Use and Spending Among Fee-for-Service Medicare Beneficiaries
Authors: Ishani Ganguli, Christopher Lim, Nicholas Daley, David Cutler, Meredith Rosenthal, Ateev Mehrotra
Journal: JAMA Internal Medicine (2025)

Importance Low-value care is a persistent problem with direct and cascading harms. Telemedicine is now commonly used and may reduce low-value testing by introducing barriers to completing tests at a given visit or expand opportunities for low-value testing by contributing to higher visit volumes. Objective To quantify the association between telemedicine adoption and low-value testing among fee-for-service Medicare beneficiaries. Design, Setting, and Participants In this cohort study using 100% fee-for-service Medicare claims data, US health systems were divided into quartiles based on 2020 telemedicine adoption. Beneficiary-level linear regression in difference-in-differences (DiD) analyses was used to compare beneficiaries who were continuously enrolled from 2019 through 2022 and were attributed before telemedicine adoption (2019) to high telemedicine–adopting (top quartile) vs low telemedicine–adopting (bottom quartile) health systems on low-value test and visit outcomes in 2022 vs 2019. Data were analyzed from October 2023 to December 2024. Exposure Health system telemedicine adoption. Main Outcomes and Measures Receipt of, and spending on, 20 low-value screening, preoperative, chronic condition management, and acute diagnostic tests, as well as total visits (in person and virtual). Results The sample included 1 382 033 beneficiaries who were attributed to high-telemedicine systems (mean [SD] age, 71.6 [10.5] years; 58.8% female) and 999 051 beneficiaries who were attributed to low-telemedicine systems (mean [SD] age, 71.8 [10.0] years; 57.0% female). From 2019 to 2022, those in high-telemedicine systems had a small differential rise in visits (DiD visits per beneficiary, 0.12; 95% CI, 0.03 to 0.21) and differential decreases in use of 7 of 20 low-value tests: cervical cancer screening (DiD, −0.45 percentage points [pp]; 95% CI, −0.72 to −0.17 pp), screening electrocardiograms (DiD, −1.30 pp; 95% CI, −1.96 to −0.65 pp), screening metabolic panels (DiD, −1.84 pp; 95% CI, −2.87 to −0.80 pp), preoperative complete blood cell counts (DiD, −0.64 pp; 95% CI, −1.06 to −0.22 pp), preoperative metabolic panels (DiD, −1.35 pp; −1.91 to −0.80 pp), total or free T3 (triiodothyronine) level testing for hypothyroidism (DiD, −0.90 pp; 95% CI, −1.38 to −0.41 pp), and imaging for uncomplicated low back pain (DiD, −1.66 pp; 95% CI, −2.35 to −0.98 pp). There were no statistically significant differences in other tests. Those in high-telemedicine systems saw statistically significant differential decreases in spending on visits per beneficiary (−$47.87; 95% CI, −$86.85 to −$8.88) and on 2 of 20 low-value tests, but no differences in low-value spending overall. Conclusions and Relevance In this cohort study, telemedicine adoption was associated with modestly lower use of 7 of 20 examined low-value tests (most point-of-care) and no changes in use of other low-value tests, despite a small rise in total visits that might offer more testing opportunities. Results suggest possible benefits of telemedicine and mitigate concerns about telemedicine contributing to increased spending.